Movement Alert|Argenx SE Intraday Rise 5.75% in Regular Trading, RBC Says Celiac Breakthrough May Be Undervalued

Market Focus10-21

On October 21, Argenx SE rose 5.75% in Regular Trading, trading at $873.085, with turnover of $250 million.

The move followed a fresh brokerage note saying the stock's recent volatility has been driven by drug-development updates and that investors may be undervaluing the company's breakthrough in celiac disease, while maintaining an outperform view.

Recent background has been mixed: positive phase 3 data in August showed Vyvgart Hytrulo met its primary endpoint in autoimmune myositis, helping lift sentiment, while an October decision to discontinue the phase 3 Sjogren's disease trial after a futility review pressured shares. At the same time, the company said its phase 2 FB102 study in celiac disease met the primary endpoint, with statistically significant and clinically relevant efficacy and no new safety signals, which appears to be supporting sentiment recovery.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment